AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
News|Articles|March 3, 2026
5 Hematology Headlines You Missed in February 2026
Author(s)Alex Hillenbrand
Fact checked by: Abigail Brooks, MA
In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.
Advertisement
Advertisement
In February 2026, the
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.
Advertisement
Advertisement